
Opinion|Videos|December 23, 2024
Examining Axatilimab in the AGAVE-201 Trial For cGVHD
Author(s)Sergio A. Giralt, MD
Sergio A. Giralt, MD, discusses how the mechanism of action of axatilimab, recently approved by the FDA for chronic graft-vs-host disease (cGVHD), involves targeting CSF1R to disrupt macrophage differentiation and reduce inflammation, and how the AGAVE-201 trial demonstrated strong efficacy and safety, which will influence clinical decision-making and potentially change the GVHD treatment landscape by offering a novel therapeutic option.
Advertisement
Video content above is prompted by the following:
- What did this abstract elucidate about the mechanism of action of axatilimab, which was approved by the FDA this year as a treatment for chronic graft-vs-host disease (cGVHD)?
- How will this abstract affect your clinical decision-making?
- The AGAVE-201 trial led to the approval of axatilimab for cGVHD. Discuss the methods and study design of this trial.
- What were the key efficacy and safety data seen in the AGAVE-201 trial with axatilimab?
- How do these results influence your clinical practice?
- How do you see the GVHD treatment landscape changing with the introduction of axatilimab?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

Obinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.

Infectious disease and urology clinicians described unclear treatment goals, infusion limits, and access barriers for newer UTI agents.

New ACACIA-HCM analyses at HCMS 2026 add imaging and quality-of-life data as Cytokinetics readies an FDA filing in nonobstructive HCM.

An oral SERD plus everolimus cut the risk of progression or death by 62% in ESR1-mutated advanced breast cancer.

New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.

Phase 3 OASIZ-301 data at ACR 2026 show dazodalibep lowered systemic activity in Sjögren disease, with dryness gains at the every-4-weeks dose.
Advertisement
Advertisement
Trending on AJMC
1
Emerging Threats to Cell and Gene Therapy Access
2
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
3
FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer
4
FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR
5

